Introduction
============

The F-box protein S-phase kinase associated protein 2 (Skp2), a component of the Skp1-Cullin 1-F-box E3 ubiquitin-ligase complex, promotes the degradation of the cyclin-dependent kinase inhibitor p27, a key regulator of G~1~ progression. An inverse correlation between Skp2 and p27 protein level has been reported in tumors ([@b1-ol-0-0-9000],[@b2-ol-0-0-9000]). Under physiological conditions, Skp2 controls the initiation of mitosis in that its expression peaks at the S and G~2~ phases, but not at G~0~ and G~1~ phases ([@b3-ol-0-0-9000],[@b4-ol-0-0-9000]). Skp2 is key in the p27 ubiquitin degradation pathway and may inhibit the proliferation of a variety of cell types through the ubiquitin-proteasome pathway ([@b4-ol-0-0-9000]--[@b6-ol-0-0-9000]).

Skp2 overexpression has been observed in various human cancers, including lymphomas ([@b7-ol-0-0-9000]), prostate cancer ([@b8-ol-0-0-9000]), melanoma ([@b9-ol-0-0-9000]), pancreatic cancer ([@b10-ol-0-0-9000]), gastric cancer ([@b11-ol-0-0-9000]), breast cancer ([@b12-ol-0-0-9000]), colorectal cancer ([@b13-ol-0-0-9000]) and lung cancer ([@b14-ol-0-0-9000],[@b15-ol-0-0-9000]).

The involvement of Skp2 overexpression in metastasis and aggressiveness has been reported in many tumors including melanoma ([@b9-ol-0-0-9000]), pancreatic cancer ([@b10-ol-0-0-9000]), breast ([@b12-ol-0-0-9000]), colorectal cancer ([@b13-ol-0-0-9000]) and lung cancer ([@b1-ol-0-0-9000]). Skp2 is also considered to be associated with the occurrence, development and prognosis of malignant tumors such as breast cancer ([@b12-ol-0-0-9000]), melanoma ([@b9-ol-0-0-9000]), prostate cancer ([@b8-ol-0-0-9000]), colorectal cancer ([@b14-ol-0-0-9000]), and lung cancer ([@b1-ol-0-0-9000]).

Expression of Skp2 is significantly upregulated in primary non-small cell lung cancer (NSCLC), compared with non-tumorous lung tissues ([@b16-ol-0-0-9000]). In patients with NSCLC, overexpression of the Skp2 protein is associated with numerous clinicopathological parameters, including histology, lymph node metastasis, smoking status, differentiation and tumor stage ([@b1-ol-0-0-9000],[@b16-ol-0-0-9000]). In addition, the positive expression of Skp2 is correlated with a poor prognosis in patients with NSCLC ([@b1-ol-0-0-9000]).

Concerning the two major pathological types of NSCLC, Skp2 is notably overexpressed in lung squamous cell carcinoma (LUSC), compared with lung adenocarcinoma (LUAD) ([@b1-ol-0-0-9000]). Due to the limitation of sample amounts, it remains unclear whether Skp2 expression is associated with those clinicopathological features in LUAD and LUSC, respectively; therefore, a study with a greater number of patients and specimens is required to compare the clinicopathological and prognostic implications with the Skp2 expression in these NSCLC types.

In the present study, the correlation between clinicopathological features and Skp2 protein expression was investigated in 351 LUAD and 149 LUSC samples. Additionally, the prognostic value of Skp2 protein expression was also investigated. Bioinformatics analyses were performed to investigate Skp2 expression-associated mRNAs and lung cancer mutations.

Materials and methods
=====================

### Cases and specimens

Patients were excluded due to chemotherapy or radiotherapy prior to surgery. A total of 351 patients with LUAD and 149 patients with LUSC who were diagnosed and underwent surgery at Peking University People\'s Hospital (Beijing, China) between January 2004 and December 2012 were enrolled in the present study. The patients included 305 males and 195 females, with a median age of 64 years (range, 24--86). All procedures performed in the current study involving human participants were in accordance with the ethical standards of the Ethics Committee of Peking University People\'s Hospital. Informed consent was obtained from all individual participants included in the study. All patients were followed up following surgery at 3--6 month intervals, and the total follow-up periods ranged from 4.8 to 7.6 years, with a median of 5.9 years. Complete clinical information from the clinical and pathological records, including sex, age, tumor size, lymphatic invasion, differentiation grade and pathological histology were collected and summarized in [Table I](#tI-ol-0-0-9000){ref-type="table"}.

Normal tissue was collected from at \>2 cm away from the primary cancer site and histopathologically identified as normal by a pathologist at the Peking University People\'s Hospital. Fresh tissue samples from each patient were formalin-fixed (10%) at room temperature overnight, paraffin-embedded and constructed into tissue microarrays (TMA).

### TMA and immunohistochemistry (IHC)

TMA were prepared using carefully identified representative core-tissue specimens (2 mm in diameter) as previously described ([@b17-ol-0-0-9000]). Sections 4 µm thick from the recipient blocks were cut. Antigen retrieval was performed in a pressure cooker, followed by treatment with 3% hydrogen peroxide for 15 min to block endogenous peroxidase activity. IHC analysis was performed using an antibody against Skp2 at room temperature for 2 h (1:200 dilution; cat. no. 2652; Cell Signaling Technology, Beverly, MA, USA). The sections were rinsed and incubated for 30 min with biotinylated second antibody in room temperature. Expression of Skp2 was detected using a diaminobenzidine reaction for 30 min and hematoxylin counterstaining for 30 sec at room temperature. There were two independent pathologists, who were blind to the patients\' clinical data, who scored the staining intensity level as follows: Level-0, negative; level-1, weak positive; level-2, moderate positive; level-3, strong positive, and the percentage of positive cells. Skp2 protein expression assessment was based on the method of a semi-quantitatively scoring system ([@b18-ol-0-0-9000]). The final score was obtained from multiplying the staining intensity level and the percentage of positively stained cells (A for level-1, B for level-2, C for level-3). The calculation formula was as follows: Score = 1×A% + 2×B% + 3×C%. The semi-quantitative method provided further information regarding the expression of Skp2 and reduced bias, whilst analyzing the correlation with clinicopathological characters.

### Skp2 co-expression analysis of LUAD and LUSC differential mRNAs

The Cancer Genome Atlas (TCGA) mRNA-expression data for LUSC and LUAD were obtained from Firehose (<http://gdac.broadinstitute.org/>) using the Bioconductor package RTCGAToolbox (version 2.4.0; <http://bioconductor.org/packages/RTCGAToolbox/>). For LUAD, a provisional dataset of 162 total tumors was used, and for LUSC, 240 samples were used.

Differential mRNAs were screened using the Bioconductor package edgeR (version 3.16.5; <http://bioconductor.org/packages/edgeR/>) ([@b19-ol-0-0-9000]). The FDR threshold was set to 0.05, in order to identify significantly deviating genes between LUAD and LUSC. The LogFC threshold was set to 1.5 to select mRNAs for the following co-expression analysis. The R statistical language (version3.4.1; <http://www.r-project.org/>) was used to conduct these analyses.

The spearman rank correlation method was used to assess the co-expression of the differential mRNAs. The top 50 Skp2-associated mRNAs were cluster analyzed and plotted by R package heatmap (version1.0.8; <http://CRAN.R-project.org/package=pheatmap>). The highest associated mRNAs were processed in The Database for Annotation, Visualization and Integrated Discovery functional annotation bioinformatics analysis ([@b20-ol-0-0-9000],[@b21-ol-0-0-9000]).

TCGA gene expression and mutation data for LUAD and LUSC were obtained from the cBioPortal for Cancer Genomics ([www.cbioportal.org](www.cbioportal.org)) ([@b22-ol-0-0-9000],[@b23-ol-0-0-9000]). For LUAD, the provisional dataset of 522 total tumors was used. Mutation data were obtained for tumor protein P53 (TP53), KRAS, Kelch-like ECH-associated protein 1 (KEAP1), serine/threonine kinase 11, epidermal growth factor receptor, neurofibromin 1 (NF1), SET domain containing 2, RNA binding motif protein 10, MGA, MET, AT-rich interaction domain 1A, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA), SWI/SNF-associated matrix-associated actin dependent regulator of chromatin subfamily A member 4, RB transcriptional corepressor 1 (RB1), cyclin dependent kinase inhibitor 2A (CDKN2A), U2 small nuclear RNA auxiliary factor 1, Ras-like without CAAX 1, Erb-B2 receptor tyrosine kinase 2 and ALK. For LUSC, data were obtained from the provisional dataset of 504 samples. Mutation data were obtained for TP53, CDKN2A, phosphatase and tensin homolog (PTEN), PIK3CA, KEAP1, major histocompatibility complex class I A, nuclear factor erythroid 2 like 2 (NFE2L2), NOTCH1 and RB1.

### Statistical analysis

Median score and 5--95 percentile were plotted. Skp2 expression among different groups according to pathological grading, lymph node metastasis, smoking status and differentiation grade were evaluated by Kruskal-Wallis H-test which is a non-parametric method for testing whether samples originate from the same distribution. Wilcoxon matched-pairs signed rank test were used to compare Skp2 expression in LUAD and LUSC Pearson\'s χ^2^ was used to compare Skp2 expression in other clinical features, including histological, age, sex, tumor size and distant metastasis. Disease-free survival (DFS) was defined as the period between surgery and the date of recurrence, and overall survival (OS) was considered as the interval from surgery to the date of mortality or final follow-up. Kaplan-Meier method with the log-rank test was performed to determine the difference in survival between groups. Cox proportional hazards regression analysis was performed to estimate the hazard ratios for positive risk factors with the backward conditional elimination method ([@b24-ol-0-0-9000]). P\<0.05 was considered to indicate a statistically significant difference (two sided). SPSS 22.0 statistic software (IBM Corp., Armonk, NY, USA) and GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA) were used to perform the computation for all statistical analyses.

Results
=======

### Correlation between Skp2 protein expression assessed by TMA-IHC and clinicopathological parameters in LUSC and LUAD

Skp2 protein expression was assessed by TMA-IHC analysis in the primary lung cancer tissues. Skp2 staining was primarily localized in the nuclear area, which is consistent with a previous study ([@b2-ol-0-0-9000]) ([Fig. 1](#f1-ol-0-0-9000){ref-type="fig"}). Another previous study indicated that Skp2 expression was significantly higher in LUSC, compared with LUAD, which was verified in the present study (P\<0.0001; [Fig. 1A and B](#f1-ol-0-0-9000){ref-type="fig"}). The median score of Skp2 in LUAD and LUSC were 0.00 and 0.375, respectively. In NSCLC (LUAD and LUSC), the 25th, 50th, 75th quartiles of Skp2 expression final score were 0.000, 0.025 and 0.250. Distribution of the Skp2 expression score in the three intervals were notably different. The majority of Skp2 expression scores were \<0.025 in the LUAD group, while scores \>0.250 were observed more frequently in LUSC ([Fig. 1C](#f1-ol-0-0-9000){ref-type="fig"}). Based on these data, subgroups analysis was proceeded in LUAD and LUSC, separately. A score of 0.025 was used to define high expression and low expression in LUAD, and a score of 0.250 in LUSC was used identically.

In LUAD, Skp2 expression varied in different groups according to sex, differentiation, smoking history, Tumor-Node-Metastasis (TNM) stage ([@b25-ol-0-0-9000]), lymph node metastasis and tumor diameter (P\<0.05; [Table I](#tI-ol-0-0-9000){ref-type="table"}). In LUSC, Skp2 protein expression correlated with smoking status (P\<0.05; [Table I](#tI-ol-0-0-9000){ref-type="table"}), whilst it demonstrated limited correlation with other clinical features.

### Prognostic significance of Skp2 protein expression in LUAD

There were three patients who succumbed during the follow-up, shortly following leaving the hospital. Survival analyses were performed in 348 patients with LUAD, of which 120 patients had a high expression of Skp2 and 228 patients had a low expression. Kaplan-Meier survival analysis with log-rank test indicated that a high Skp2 protein expression in patients with LUAD was significantly associated with a reduced DFS and OS (P\<0.001; [Fig. 2A and B](#f2-ol-0-0-9000){ref-type="fig"}). The 5-year OS in the Skp2-H group was 61.9%, compared with a rate of 86.9% in the Skp2-L group. For patients with LUSC, no association was observed between Skp2 expression and the outcome of patients ([Fig. 2C and D](#f2-ol-0-0-9000){ref-type="fig"}).

Cox proportional hazards model was used to determine the association of six factors (sex, age, differentiation, pathological stage, smoking status and Skp2 protein expression) with the OS of patients with LUAD. As a result, Skp2 protein highly expression was demonstrated to be an independent prognostic factor of OS, with a relative risk of 1.845 (P=0.030). Poor differentiation (P=0.016) and high stage (P\<0.001) were associated with a reduced OS also ([Table II](#tII-ol-0-0-9000){ref-type="table"}).

### Histological differential mRNAs and frequent mutations association with Skp2

Association analysis and cluster analysis screened nine Skp2 co-expression mRNAs \[cell division cycle 45 (CDC45), replication factor C subunit 4 (RFC4), actin like 6A (ACTL6A), family with sequence similarity 83 member D, E2F transcription factor 7, chromosome 15 open reading frame 42 (C15orf42), DNA polymerase θ (POLQ), Skp2 and minichromosome maintenance complex component 2 (MCM2)\], which are also differential between LUAD and LUSC. Skp2, CDC45 and MCM2 are involved in the G~1~/S transition of the mitotic cell cycle. CDC45, MCM2, RFC4, POLQ and ACTL6A participate in DNA replication and repair ([Fig. 3](#f3-ol-0-0-9000){ref-type="fig"}).

In the TCGA cohort of patients with LUAD and LUSC, Skp2 expression was highly expressed in the TP53, NF1 and RB1 mutation groups, compared with the unaltered group. The KRAS mutation group had a lower Skp2 expression in LUAD. Whilst in LUSC, it was determined that there was a significant deviation of Skp2 expression in the four other commonly mutated genes, PTEN, PIK3CA, KEAP1 and NFE2L2 ([Table III](#tIII-ol-0-0-9000){ref-type="table"}).

Discussion
==========

LUAD and LUSC are the NSCLC types with the highest prevalence, accounting for 80--85% of lung cancer types. Large-scale sequencing studies have revealed the genomic differences between LUAD and LUSC ([@b26-ol-0-0-9000]). The molecular mechanisms underlying LUAD and LUSC are considerably different ([@b27-ol-0-0-9000]). A previous study demonstrated that the Skp2 relative gene copy number aberrations were detected in NSCLC, and these changes are reflected at the mRNA and protein expression levels ([@b16-ol-0-0-9000]).

In the present study, Skp2 protein has different expression patterns in LUSC and LUAD; therefore the association between Skp2 expression and clinicopathological parameters in patients with LUAD and LUSC were evaluated. The data indicated that clinicopathological and prognostic implications based on Skp2 expression in LUAD and LUSC should be considered different.

The data indicated that high expression of Skp2 in LUSC would result in abnormal activation of DNA replication and G~1~/S transition pathways. This indicated that alterations of lung cancer associated oncogenes modulating these pathways may contribute to the aberration of Skp2 expression. The association between lung cancer mutations and Skp2 expression were then investigated. Skp2 was expressed higher in the lung cancer-associated genes altered group, except in the KRAS mutation group. KRAS has a mutation rate of 19.7% in LUAD, which is more frequent than LUSC; however, PTEN, PIK3CA, KEAP1 and NFE2L2, which induce the proliferation of cancer cells, are present more frequently in LUSC. Different driver gene mutation frequencies may be one reason for the distinct expression patterns of Skp2 in LUSC and LUAD; however, this would not fully explain the difference of Skp2 expression between LUAD and LUSC. Further study focusing on the regulation of Skp2 expression are required, including the regulated relationship with deviated miRNAs and lncRNAs.

Skp2 has a function in promoting cell growth ([@b28-ol-0-0-9000]). A previous study primarily focused on the T stage ([@b29-ol-0-0-9000]). In the present study, Skp2 overexpression was associated with the tumor diameter more significantly than T stage (P\<0.001 vs. P=0.221; [Table I](#tI-ol-0-0-9000){ref-type="table"}). Ina ddition to the T stage, continued studies must also consider pleural invasion and the distance to the carina of the trachea, but these features are not affected by tumor proliferation ability.

The prognostic value of Skp2 expression in NSCLC has been controversial. Osoegawa *et al* ([@b1-ol-0-0-9000]) indicated that a high Skp2 protein expression was an independent poor prognostic marker in NSCLC; however, Zhu *et al* ([@b30-ol-0-0-9000]) reported that Skp2 overexpression was not prognostically significant alone, but along with a RAS mutation was a significant independent poor prognostic marker in NSCLC. In the present study, it was demonstrated that a high expression of Skp2 may indicate a poor prognosis in LUAD, but it was not observed in LUSC. Additionally, in KRAS-mutated LUAD, Skp2 had a lower expression level, compared with the unaltered group. This may indicate that Skp2 may have clinicopathological and prognostic implications when it is expressed at a relatively lower level.

Detection of Skp2 overexpression may be a beneficial marker for prognosis. Skp2 may provide sputum-based markers that have the potential to improve the early detection of LUSC ([@b31-ol-0-0-9000]). Skp2 can also be detected in the peripheral blood of patients with NSCLC, and has demonstrated high diagnostic value ([@b32-ol-0-0-9000]). These studies provide evidence that detection of Skp2 expression level should be conducted prior to surgery, assisting with the decision for surgery procedure; however, the molecular mechanism underlying regulation of Skp2 in lung cancer remains unclear and further *in vitro* and *in vivo* investigations are required.

To conclude, Skp2 protein expression has different patterns between LUAD and LUSC. The clinicopathological and prognostic implications based on Skp2 expression in LUAD and LUSC should be considered different. Differential expression of Skp2 protein expression was associated with an unfavorable outcome in patients with LUAD, but not in LUSC. Skp2-H LUSC may have robust proliferation ability.
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![Skp2 expression in lung cancers. (A) Immunohistochemical staining of Skp2 in LUAD, LUSC and adjacent normal tissue (magnification, ×100). Red rectangles indicate that the areas been magnified. Scale bars, 100 µm. (B) Boxplot of Skp2 expression scores in LUAD and LUSC. (C) Distribution of Skp2 expression score in the four intervals based on the 25th, 50th and 75th percentile in non-small cell lung cancer. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; Skp2, S-phase kinase associated protein 2.](ol-16-03-2873-g00){#f1-ol-0-0-9000}

![Kaplan-Meier survival analysis for patients with LUAD and LUSC with Skp2-H and Skp2-L. (A) DFS in patients with LUAD. (B) OS in patients with LUAD. (C) DFS in patients with LUSC. (D) OS in patients with LUSC. Skp2-L, Skp2 low expression; Skp2-H, Skp2 high expression; OS, overall survival; DFS, disease-free survival; Skp2, S-phase kinase associated protein 2; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.](ol-16-03-2873-g01){#f2-ol-0-0-9000}

![Heatmap with clustering analysis of the top 50 S-phase kinase associated protein 2 co-expressed mRNAs, which were differential between lung adenocarcinoma and lung squamous cell carcinoma.](ol-16-03-2873-g02){#f3-ol-0-0-9000}

###### 

Correlation between Skp2 protein expression and clinicopathological parameters in lung cancers.

                                     LUAD       LUSC                                                                                                                                                                                                  
  ---------------------------------- ---------- ------ ----- ----- ------------------------------------------------------ ------------------------------------------------------ ----- ---- ---- ---------------------------------------------------- ----------------------------------------------------
  Total                                         351    231   120                                                                                                                 149   54   95                                                        
  Sex                                Male       172    102   70      6.325^[b](#tfn2-ol-0-0-9000){ref-type="table-fn"}^   0.012^[a](#tfn1-ol-0-0-9000){ref-type="table-fn"}^     133   48   85   0.012^[b](#tfn2-ol-0-0-9000){ref-type="table-fn"}^   0.912
                                     Female     179    129   50                                                                                                                  16    6    10                                                        
  Age                                \<65       186    129   57      2.207^[b](#tfn2-ol-0-0-9000){ref-type="table-fn"}^   0.137                                                  81    34   47   2.525^[b](#tfn2-ol-0-0-9000){ref-type="table-fn"}^   0.112
                                     ≥65        165    102   63                                                                                                                  68    20   48                                                        
  Differentiation                    Well       107    91    16    36.308^[c](#tfn3-ol-0-0-9000){ref-type="table-fn"}^    \<0.001^[a](#tfn1-ol-0-0-9000){ref-type="table-fn"}^   11    7    4    2.898^[c](#tfn3-ol-0-0-9000){ref-type="table-fn"}^   0.235
                                     Moderate   122    78    44                                                                                                                  68    25   43                                                        
                                     Poor       122    62    60                                                                                                                  70    22   48                                                        
  Smoking status (cigarettes/year)   0          232    163   69    16.198^[c](#tfn3-ol-0-0-9000){ref-type="table-fn"}^    \<0.001^[a](#tfn1-ol-0-0-9000){ref-type="table-fn"}^   31    14   17   6.555^[c](#tfn3-ol-0-0-9000){ref-type="table-fn"}^   0.038^[a](#tfn1-ol-0-0-9000){ref-type="table-fn"}^
                                     0\<n≤400   62     41    21                                                                                                                  30    7    23                                                        
                                     \>400      57     27    30                                                                                                                  88    33   55                                                        
  T                                  1          157    110   47      4.410^[c](#tfn3-ol-0-0-9000){ref-type="table-fn"}^   0.221                                                  30    9    21   0.653^[c](#tfn3-ol-0-0-9000){ref-type="table-fn"}^   0.884
                                     2          170    110   60                                                                                                                  86    35   51                                                        
                                     3          13     6     7                                                                                                                   26    8    18                                                        
                                     4          11     5     6                                                                                                                   7     2    5                                                         
  N                                  0          233    174   59    24.081^[c](#tfn3-ol-0-0-9000){ref-type="table-fn"}^    \<0.001^[a](#tfn1-ol-0-0-9000){ref-type="table-fn"}^   72    23   49   2.564^[c](#tfn3-ol-0-0-9000){ref-type="table-fn"}^   0.464
                                     1          35     17    18                                                                                                                  33    13   20                                                        
                                     2          79     37    42                                                                                                                  43    17   26                                                        
                                     x          4      3     1                                                                                                                   1     1    0                                                         
  M                                  0          334    219   115     0.181^[b](#tfn2-ol-0-0-9000){ref-type="table-fn"}^   0.670                                                  146   52   94   1.227^[b](#tfn2-ol-0-0-9000){ref-type="table-fn"}^   0.268
                                     1          17     12    5                                                                                                                   3     2    1                                                         
  TNM stage                          I          215    165   50    33.202^[c](#tfn3-ol-0-0-9000){ref-type="table-fn"}^    \<0.001^[a](#tfn1-ol-0-0-9000){ref-type="table-fn"}^   54    19   35   1.127^[c](#tfn3-ol-0-0-9000){ref-type="table-fn"}^   0.771
                                     II         44     19    25                                                                                                                  41    14   27                                                        
                                     III        75     35    40                                                                                                                  51    19   32                                                        
                                     IV         17     12    5                                                                                                                   3     2    1                                                         
  Diameter                           ≤3 cm      270    195   75    21.368^[b](#tfn2-ol-0-0-9000){ref-type="table-fn"}^    \<0.001^[a](#tfn1-ol-0-0-9000){ref-type="table-fn"}^   47    15   32   0.556^[b](#tfn2-ol-0-0-9000){ref-type="table-fn"}^   0.456
                                     \>3 cm     81     36    45                                                                                                                  102   39   63                                                        

P\<0.05.

Z-value from Kruskal-Wallis H-test.

χ^2^ value from Pearson\'s χ^2^ test. Skp2, S-phase kinase associated protein 2; TNM, tumor-node-metastasis; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; x, lymph node metastasis could not be assessed.

###### 

Multivariate analysis for prognostic factors in patients with lung adenocarcinoma.

                                                                                        OS                                       
  ------------------------------------------------------------------------------------- -------- ------- ------- --------------- ------------------------------------------------------
  Sex (male vs. female)                                                                 −0.221   0.273   0.801   0.469--1.368    0.417
  Age (\<65 vs. ≥65)                                                                    0.536    0.277   1.709   0.993--2.941    0.053
  Differentiation (well/moderate vs. poor)                                              1.282    0.531   3.604   1.272--10.214   0.016^[a](#tfn4-ol-0-0-9000){ref-type="table-fn"}^
  TNM stage (stage I vs. stages II--IV)                                                 1.484    0.324   4.413   2.340--8.320    \<0.001^[a](#tfn4-ol-0-0-9000){ref-type="table-fn"}^
  Smoking status (non-smoker^[b](#tfn5-ol-0-0-9000){ref-type="table-fn"}^ vs. smoker)   −0.322   0.354   0.752   0.362--1.452    0.364
  Skp2 expression (low vs. high)                                                        0.613    0.283   1.845   1.060--3.212    0.030^[a](#tfn4-ol-0-0-9000){ref-type="table-fn"}^

P\<0.05.

Never smoked. TNM, tumor-node-metastasis; CI, confidence interval; S.E., standard error; OS, overall survival; Skp2, S-phase kinase associated protein 2.

###### 

Deviation of S-phase kinase associated protein 2 expression with lung cancer mutations.

                             Mean   SD                                  
  ------ ------------------- ------ ------ ------ ------ -------------- --------------
  LUAD   TP53 (111/21.3%)    7.44   7.05   1.08   0.97   9.270×10^−4^   7.036×10^−3^
         KRAS (103/19.7%)    6.90   7.20   0.79   1.04   1.639×10^−3^   0.0324
         NF1 (29/13%)        7.61   7.10   1.02   1.00   0.0102         0.193
         RB1 (17/7.4%)       7.98   7.10   1.00   0.99   3.696×10^−4^   0.0178
  LUSC   TP53 (150/29.8%)    9.22   8.79   0.83   0.96   6.32×10^−7^    6.708×10^−6^
         PTEN (74/14.7%)     9.24   8.87   0.86   0.95   1.091×10^−3^   0.119
         PIK3CA (251/49.8)   9.06   8.77   0.83   1.03   5.430×10^−4^   2.352×10^−3^
         KEAP1 (40/7.9%)     9.28   8.89   0.90   0.94   0.0104         0.0869
         NFE2L2 (58/11.5%)   9.16   8.88   0.88   0.95   7.959×10^−3^   0.0348
         RB1 (33/6.5%)       9.39   8.88   0.90   0.94   1.199×10^−3^   0.0394

SD, standard deviation; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; TP53, tumor protein P53; NF1, neurofibromin 1; RB1, RB transcriptional corepressor 1; PTEN, phosphatase and tensin homolog; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α; KEAP1; Kelch-like ECH-associated protein 1; NFE2L2, nuclear factor erythroid 2 like 2.
